Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
Key facts
- Who runs it
- Yale University
- Where
- Hartford, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 78 people enrolled
- Started
- 17 May 2022
- Ended
- 31 May 2026
- Type of study
- Interventional, 4 groups
- Treatments tested
- Mavoglurant (AFQ056)
- Placebo
- Record updated
- 24 September 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Ages 18-45 years
- Estimated full-scale IQ>70
- Individual can cooperate with all study procedures
- No history of neurological disorder (e.g., epilepsy)
- No major medical condition (e.g., cancer)
- No history of significant head trauma
- Stable medication treatment 6 weeks prior to study enrollment
- Negative urine drug and breathe alcohol test at time of MRI scan
- Negative urine pregnancy test at time of MRI scan
- No MR contra-indications (e.g., in-body metal implant, severe claustrophobia)
- No contra-indications to study drug
Who cannot take part
- A current diagnosis of: a) Alcohol use disorder, if severe (AUD, mild or moderate OK if no craving, tolerance, and withdrawal 3 months prior to interview) b) Substance use disorder
- Women not on an effective form of birth control/contraception or abstinent during time of study visits to prevent exposure of the investigational drug to suspected fetus
- A diagnosis of any psychotic disorder, or current mood or anxiety disorders under DSM-V, using the SCID-V-RV psychiatric interview
- Report of psychotic disorder in a 1º relative
- Auditory or visual impairment that interferes with test-taking
- Prenatal exposure to alcohol plus currently meeting criteria for features of fetal alcohol syndrome
- Presence or history of neurosurgery or any neurologic illness that may affect brain physiology (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural MRI (all structural scans are read by a board certified radiologist)
- A current major medical condition (e.g. cancer, heart failure)
- Not speaking English fluently or being a non-native English speaker, or being educated in a primary language other than English > grade 1
- Intellectual Disability (Full Scale IQ<70)
- Traumatic brain injury with loss of consciousness > 30 minutes or concussion in last 30 days
- Current pregnancy (all females will be tested with urine screens on the day of MRI)
- Current substance use with the exception of marijuana (THC), provided last use of THC was 24+ hours before visit (All participants will receive a urine screen for the presence of marijuana, cocaine, opiates and a breath screen to detect the presence of alcohol)
- Inability to comprehend the consent form appropriately
- Inability to cooperate with study procedures
- Other specific fMRI exclusions include metal devices, clips or fragments in body (orbital xray performed if needed)
Where in United States
- Hartford HospitalHartford, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
The 4 groups in the trial
- FHP; Mavoglurant-PlaceboTreatment being tested
Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
Treatment: Mavoglurant (AFQ056) and Placebo
- FHP; Placebo-MavoglurantTreatment being tested
Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
Treatment: Mavoglurant (AFQ056) and Placebo
- FHN; Mavoglurant-PlaceboTreatment being tested
Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
Treatment: Mavoglurant (AFQ056) and Placebo
- FHN; Placebo-MavoglurantTreatment being tested
Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
Treatment: Mavoglurant (AFQ056) and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 September 2026